Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FUSNNASDAQ:MESONASDAQ:MOLNNASDAQ:VIGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFUSNFusion Pharmaceuticals$21.55$21.50$2.31▼$21.60$1.83B-0.691.69 million shsN/AMESOMesoblast$10.16-2.7%$11.31$5.78▼$22.00$1.33B2.41275,121 shs403,844 shsMOLNMolecular Partners$3.58-8.0%$3.89$3.36▼$12.22$157.06M1.1215,367 shs3,191 shsVIGLVigil Neuroscience$7.94+0.3%$4.80$1.31▼$7.95$369.64M3.4743,926 shs707,827 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFUSNFusion Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MESOMesoblast0.00%-11.38%-3.78%-27.45%+48.93%MOLNMolecular Partners0.00%-4.91%-9.20%-7.16%-61.66%VIGLVigil Neuroscience0.00%+0.76%+0.38%+316.84%+105.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFUSNFusion PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMESOMesoblast2.5647 of 5 stars3.53.00.00.02.80.80.6MOLNMolecular Partners2.3082 of 5 stars3.85.00.00.00.00.00.6VIGLVigil Neuroscience3.639 of 5 stars4.05.00.00.02.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFUSNFusion Pharmaceuticals 0.00N/AN/AN/AMESOMesoblast 3.00Buy$18.0077.17% UpsideMOLNMolecular Partners 3.50Strong Buy$12.00235.20% UpsideVIGLVigil Neuroscience 2.00Hold$10.8036.02% UpsideCurrent Analyst Ratings BreakdownLatest FUSN, VIGL, MESO, and MOLN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025VIGLVigil NeuroscienceStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$11.00 ➝ $8.005/27/2025VIGLVigil NeuroscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$14.00 ➝ $8.005/23/2025VIGLVigil NeuroscienceMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/22/2025VIGLVigil NeuroscienceJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold5/22/2025VIGLVigil NeuroscienceGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Neutral$8.005/22/2025VIGLVigil NeuroscienceCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform5/22/2025VIGLVigil NeuroscienceGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/22/2025VIGLVigil NeuroscienceCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/22/2025VIGLVigil NeuroscienceJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Perform5/22/2025VIGLVigil NeuroscienceWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$13.00 ➝ $8.003/31/2025MESOMesoblastCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFUSNFusion Pharmaceuticals$2.07M885.53N/AN/A$3.07 per share7.02MESOMesoblast$5.90M220.04N/AN/A$4.21 per share2.41MOLNMolecular Partners$5.65M25.59N/AN/A$3.99 per share0.90VIGLVigil NeuroscienceN/AN/AN/AN/A$1.75 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFUSNFusion Pharmaceuticals-$94.90M-$1.42N/AN/AN/A-4,136.55%-48.74%-36.87%N/AMESOMesoblast-$87.96MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)MOLNMolecular Partners-$61.39M-$1.92N/AN/AN/A-1,043.01%-42.20%-38.12%8/25/2025 (Estimated)VIGLVigil Neuroscience-$84.26M-$2.05N/AN/AN/AN/A-111.70%-74.67%8/12/2025 (Estimated)Latest FUSN, VIGL, MESO, and MOLN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025MOLNMolecular Partners-$0.3855-$0.50-$0.1145-$0.50N/AN/A5/7/2025Q1 2025VIGLVigil Neuroscience-$0.53-$0.49+$0.04-$0.49N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFUSNFusion PharmaceuticalsN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/AVIGLVigil NeuroscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFUSNFusion Pharmaceuticals0.2110.6410.64MESOMesoblast0.220.960.63MOLNMolecular PartnersN/A15.2815.28VIGLVigil NeuroscienceN/A2.972.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFUSNFusion Pharmaceuticals72.85%MESOMesoblast1.43%MOLNMolecular Partners26.55%VIGLVigil Neuroscience83.64%Insider OwnershipCompanyInsider OwnershipFUSNFusion Pharmaceuticals7.75%MESOMesoblast18.80%MOLNMolecular Partners5.93%VIGLVigil Neuroscience18.01%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFUSNFusion Pharmaceuticals10185.06 million78.47 millionOptionableMESOMesoblast80127.78 million103.76 millionOptionableMOLNMolecular Partners18040.38 million37.98 millionNot OptionableVIGLVigil Neuroscience4046.67 million38.27 millionNot OptionableFUSN, VIGL, MESO, and MOLN HeadlinesRecent News About These CompaniesVigil Neuroscience, Inc. (NASDAQ:VIGL) Receives $10.80 Consensus Price Target from AnalystsJune 20 at 1:20 AM | americanbankingnews.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Receives Consensus Rating of "Hold" from AnalystsJune 17, 2025 | marketbeat.comTwo Sigma Investments LP Acquires 41,836 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)June 12, 2025 | marketbeat.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of ShareholdersJune 9, 2025 | prnewswire.comWall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a BetJune 9, 2025 | zacks.comSquarepoint Ops LLC Acquires New Shares in Vigil Neuroscience, Inc. (NASDAQ:VIGL)June 9, 2025 | marketbeat.comMillennium Management LLC Boosts Holdings in Vigil Neuroscience, Inc. (NASDAQ:VIGL)June 9, 2025 | marketbeat.comJane Street Group LLC Invests $83,000 in Vigil Neuroscience, Inc. (NASDAQ:VIGL)June 9, 2025 | marketbeat.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Holdings Lifted by Two Sigma Advisers LPJune 8, 2025 | marketbeat.comVigil Neuroscience halts Phase 2 trial for ALSP treatmentJune 5, 2025 | investing.comVigil’s TREM2 Antibody for Rare Brain Disease Flunks Phase II TrialJune 5, 2025 | biospace.comVIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors ...June 5, 2025 | morningstar.comDisappointing results see Vigil Neuro drop iluzanebart developmentJune 4, 2025 | thepharmaletter.comVIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the FirmJune 4, 2025 | prnewswire.comVigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSPJune 4, 2025 | globenewswire.comShould You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?June 2, 2025 | zacks.comHC Wainwright Has Bearish Forecast for VIGL FY2026 EarningsMay 30, 2025 | marketbeat.comStifel cuts Vigil Neuroscience stock rating, lowers target to $8May 29, 2025 | investing.comVigil Neuroscience (NASDAQ:VIGL) Downgraded by Stifel Nicolaus to HoldMay 29, 2025 | marketbeat.comStifel Downgrades Vigil Neuroscience (VIGL)May 29, 2025 | msn.comHC Wainwright Reiterates "Neutral" Rating for Vigil Neuroscience (NASDAQ:VIGL)May 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFUSN, VIGL, MESO, and MOLN Company DescriptionsFusion Pharmaceuticals NASDAQ:FUSNFusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It is conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, the company develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers.; FPI-2068, a bispecific antibody, which is in Phase 1 clinical trial targeting epidermal growth factor receptor, and mesenchymal epithelial transition factor. It has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in Hamilton, Canada.Mesoblast NASDAQ:MESO$10.16 -0.28 (-2.68%) Closing price 04:00 PM EasternExtended Trading$10.32 +0.16 (+1.57%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.Molecular Partners NASDAQ:MOLN$3.60 -0.29 (-7.33%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.Vigil Neuroscience NASDAQ:VIGL$7.94 +0.02 (+0.25%) Closing price 04:00 PM EasternExtended Trading$7.94 +0.00 (+0.06%) As of 07:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
